EC approves Novartis’s Kesimpta for relapsing multiple sclerosis
The European Commission has approved Novartis’s Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (RMS) in adults…
Novartis
-
-
Novartis to divest select Sandoz US portfolio to Aurobindo for $900m
Novartis has signed an agreement to sell parts of its Sandoz US business to Aurobindo Pharma USA for a cash…
-
Novartis receives EC approval for Kymriah to treat two cancers
The European Commission (EC) has granted approval for Novartis' Kymriah to treat patients with B-cell acute lymphoblastic leukaemia (ALL) and…
-
Novartis’ migraine drug Aimovig gets EC approval
Novartis has obtained approval from the European Commission (EC) for the use of Aimovig (erenumab) to prevent migraine in adults…
-
Novartis signs $1bn licensing deal with MorphoSys and Galapagos
Novartis Pharma has signed a worldwide, exclusive agreement to licence atopic dermatitis drug candidate MOR106, which is being jointly development…
-
FDA approves expanded indication for Novartis drug Kisqali
Novartis has obtained approval from the US Food and Drug Administration (FDA) for its Kisqali (ribociclib) to treat hormone-receptor positive,…
-
Novartis and Sandoz withdraw medicines from US over packaging concerns
Novartis and its affiliated Sandoz division have voluntarily recalled certain lots of 12 blister packs of medicines from the US…
